Investor Presentation Full Year 2017

Investor Presentation Full year 2017 Stable insulin leadership position in Region AAMEO comprising Africa, Asia, Middle-East and Oceania Region AAMEO insulin market by segment insulin volume market shares tMU 120 100 80 60 40 420 20 0 Nov 2012 - Device penetration - CAGR volume¹: 8.3% CAGR value¹: Slide 54 Region AAMEO modern and new-generation MI and NGI penetration Novo Nordisk Sanofi Eli Lilly Biocon Penetration 5.4% 100% 70% 60% 55% 80% Fast-acting 50% 60% 40% Premix 30% 40% 20% 20% Long-acting 10% 0% 0% Nov 2017 Nov 2012 21% 14% 3% Nov 2017 1 CAGR for 5-year period. Note: IQVIA only covers the following 8 markets in AAMEO (retail data): Algeria, Egypt, India, New Zealand, Russia, Saudi Arabia, South Africa & Turkey, which together account for 82% of Novo Nordisk insulin sales in AAMEO Source: IQVIA (formerly IMS) monthly MAT Nov, 2017 volume and value (DKK) figures MI: Modern insulin; NGI: New-generation insulin Source: IQVIA (formerly IMS) monthly MAT Nov, 2017 volume figures, numbers do not add up to 100% due to smaller insulin manufacturers novo nordisk

View entire presentation